1-(Alpha-(2-哌啶乙氧基羰基)苄基)氯化哌啶

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-(Alpha-(2-哌啶乙氧基羰基)苄基)氯化哌啶
• 英文名称: 1-(2-Oxo-1-phenyl-2-(2-(piperidin-1-ium-1-yl)ethoxy)ethyl)piperidin-1-ium chloride
• 英文别名: 2-piperidin-1-ium-1-ylethyl 2-phenyl-2-piperidin-1-ium-1-ylacetate;dichloride
• 化学式: C20H32Cl2N2O2
• 分子量: 403.4
• InChiKey: CBACFHTXHGHTMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.09
• 重原子数：
  26
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  32.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
  申请人：The Scripps Research Institute

  公开号：US10660899B2

  公开（公告）日：2020-05-26

  The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

  本发明提供了用神经递质受体调节剂诱导少突胶质祖细胞向成熟髓鞘细胞命运分化的方法。本发明还提供了通过施用所述神经递质受体调节剂刺激有需要的受试者增加髓鞘化的方法。本发明还提供了使用神经递质受体调节剂治疗脱髓鞘疾病的方法。
• DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE
  申请人：The Scripps Research Institute

  公开号：EP2675893A1

  公开（公告）日：2013-12-25
• US9592288B2
  申请人：——

  公开号：US9592288B2

  公开（公告）日：2017-03-14
• [EN] DIRECTED DIFFERENTIATION OF OLIGODENDROCYTE PRECURSOR CELLS TO A MYELINATING CELL FATE<br/>[FR] DIFFÉRENCIATION DIRIGÉE DE CELLULES PRÉCURSEURS D'OLIGODENDROCYTES VERS UN DESTIN CELLULAIRE MYÉLINISANT
  申请人：SCRIPPS RESEARCH INST

  公开号：WO2012112933A1

  公开（公告）日：2012-08-23

  The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.